دورة المؤشرنت للتحليل الفني
50 دينار كويتي
abi
- بادئ الموضوع ابو رواف
- تاريخ البدء
نوعا ما .
اقصد انني احنمال ان اشتري با السهم اذا نزل الى low يوم الجمعة او اذا تجاوز high يوم الجمعة . اما با المنتصف فلا ارى شيء مغري فية .
يعني , اذا نزل الى low يوم الجمعة ابشترية وابيعة عند هاي يوم الجمعة .
اما اذا اخترق هاي يوم الجمعة فسأشترية والبيع (( انا وضميري )) .
اقصد انني احنمال ان اشتري با السهم اذا نزل الى low يوم الجمعة او اذا تجاوز high يوم الجمعة . اما با المنتصف فلا ارى شيء مغري فية .
يعني , اذا نزل الى low يوم الجمعة ابشترية وابيعة عند هاي يوم الجمعة .
اما اذا اخترق هاي يوم الجمعة فسأشترية والبيع (( انا وضميري )) .
ابوابراهيم
عضو
عزيزي ابورواف
السهم عنده مقاومه صعبه جدا عند 21.5 يليت انتظرت لين يعديها
بعدها الى 22.5 ثم 23.5 ثم 24
اعتقد اذا عدى 21.5 بيكون هدفه 24 ان شاء الله
الماكد معطي بداية بولش
وفي نفس الوقت عندها دعم قوي عند 21.2
وشوف prox سعره 2.8 واعتقد ان شاء الله بيوصل 3.4 ومؤشراته طيبه
وبالتوفيق ان شاء الله
السهم عنده مقاومه صعبه جدا عند 21.5 يليت انتظرت لين يعديها
بعدها الى 22.5 ثم 23.5 ثم 24
اعتقد اذا عدى 21.5 بيكون هدفه 24 ان شاء الله
الماكد معطي بداية بولش
وفي نفس الوقت عندها دعم قوي عند 21.2
وشوف prox سعره 2.8 واعتقد ان شاء الله بيوصل 3.4 ومؤشراته طيبه
وبالتوفيق ان شاء الله
تصحيح الهدف 24.49 دولار . سيأخذ وقت , واعتقد ان الخروج قبل ذلك هو اختصار للوقت وءامن .
FOSTER CITY, Calif. (Dow Jones)--Applied Biosystems Group's (ABI) fiscal second-quarter net income rose 79% from a year ago, when asset write-offs, severance costs and office closures hurt results.
The company projects third-quarter earnings will be "slightly above" year-ago earnings of 19 cents a share, including expected legal expenses.
In a press release Wednesday, the biotechnology company said it earned $52.4 million, or 25 cents a share, for the second quarter, up from $29.2 million, or 14 cents a share, a year ago.
The latest quarter included a gain of 2 cents a share from the sale of investments and a reduction in severence costs previously recorded during the second quarter of fiscal 2003. The net effect of foreign currency benefited net income by about $2 million, or 1 cent a share.
The year-ago quarter included charges totaling 11 cents a share for asset write-offs, severance costs and office closures.
(MORE) Dow Jones Newswires
01-28-04 0732ET
DJ Applied Biosystems Earnings -3: 2Q Rev Rose 3% To $458.4M
Applied Biosystems' revenue for the second quarter increased 3% to $458.4 million from $444.7 million a year ago, driven by strength in both the sequence detection systems and other applied genomics and mass spectrometry product categories.
The net effect of foreign currency increased net revenue in the latest second quarter by about $12 million. Year-ago second-quarter revenue included $6.7 million for a genetic analysis technology license.
"Despite an uncertain outlook for government funding of life science research, we continue to expect improved revenue and earnings performance in the second half of this fiscal year compared to the prior year period," said Chief Executive Tony L. White in the release. "This expectation is based on a strong outlook for Sequence Detection Systems (SDS) and mass spectrometry products, as well as the contribution expected from new functional genomics products to be released in the coming months."
(MORE) Dow Jones Newswires
01-28-04 0749ET
DJ Applied Biosystems Earnings -4: Street Sees 3Q EPS 22c
Applied Biosystems anticipates fiscal third-quarter earnings "slightly above" year-ago earnings of 19 cents a share, including expected legal expenses. First Call projects earnings of 22 cents a share for the quarter ending March.
The company, which provides consumables, software and services, believes demand from commercial customers should improve during the remainder of fiscal 2004, but believes a number of issues relating to government funding for life science research exist that could potentially hurt second-half results.
Despite funding constraints, the company still projects single-digit annual revenue growth for fiscal 2004. For the second half of the fiscal year, the company expects new product sales will drive revenue growth. Applied Biosystems also expects 2004 annual earnings per share growth will equal or rise slightly above annual revenue growth.
For the latest year ended June 30, the company earned 95 cents a share from continuing operations, on revenue of $1.68 billion.
Applied Biosystems estimates that the fiscal 2004 annual gross margin will be about equal to that of fiscal 2003. The company expects annual selling, general and administrative expense to increase as a percent of total revenues during fiscal 2004 due to factors including expenses associated with Applera's legal actions with F. Hoffmann-La Roche Ltd. and the expected commencement next month of a patent infringement trial involving MJ Research Inc.
The company anticipates capital spending of between $70 million and $80 million.
FOSTER CITY, Calif. (Dow Jones)--Applied Biosystems Group's (ABI) fiscal second-quarter net income rose 79% from a year ago, when asset write-offs, severance costs and office closures hurt results.
The company projects third-quarter earnings will be "slightly above" year-ago earnings of 19 cents a share, including expected legal expenses.
In a press release Wednesday, the biotechnology company said it earned $52.4 million, or 25 cents a share, for the second quarter, up from $29.2 million, or 14 cents a share, a year ago.
The latest quarter included a gain of 2 cents a share from the sale of investments and a reduction in severence costs previously recorded during the second quarter of fiscal 2003. The net effect of foreign currency benefited net income by about $2 million, or 1 cent a share.
The year-ago quarter included charges totaling 11 cents a share for asset write-offs, severance costs and office closures.
(MORE) Dow Jones Newswires
01-28-04 0732ET
DJ Applied Biosystems Earnings -3: 2Q Rev Rose 3% To $458.4M
Applied Biosystems' revenue for the second quarter increased 3% to $458.4 million from $444.7 million a year ago, driven by strength in both the sequence detection systems and other applied genomics and mass spectrometry product categories.
The net effect of foreign currency increased net revenue in the latest second quarter by about $12 million. Year-ago second-quarter revenue included $6.7 million for a genetic analysis technology license.
"Despite an uncertain outlook for government funding of life science research, we continue to expect improved revenue and earnings performance in the second half of this fiscal year compared to the prior year period," said Chief Executive Tony L. White in the release. "This expectation is based on a strong outlook for Sequence Detection Systems (SDS) and mass spectrometry products, as well as the contribution expected from new functional genomics products to be released in the coming months."
(MORE) Dow Jones Newswires
01-28-04 0749ET
DJ Applied Biosystems Earnings -4: Street Sees 3Q EPS 22c
Applied Biosystems anticipates fiscal third-quarter earnings "slightly above" year-ago earnings of 19 cents a share, including expected legal expenses. First Call projects earnings of 22 cents a share for the quarter ending March.
The company, which provides consumables, software and services, believes demand from commercial customers should improve during the remainder of fiscal 2004, but believes a number of issues relating to government funding for life science research exist that could potentially hurt second-half results.
Despite funding constraints, the company still projects single-digit annual revenue growth for fiscal 2004. For the second half of the fiscal year, the company expects new product sales will drive revenue growth. Applied Biosystems also expects 2004 annual earnings per share growth will equal or rise slightly above annual revenue growth.
For the latest year ended June 30, the company earned 95 cents a share from continuing operations, on revenue of $1.68 billion.
Applied Biosystems estimates that the fiscal 2004 annual gross margin will be about equal to that of fiscal 2003. The company expects annual selling, general and administrative expense to increase as a percent of total revenues during fiscal 2004 due to factors including expenses associated with Applera's legal actions with F. Hoffmann-La Roche Ltd. and the expected commencement next month of a patent infringement trial involving MJ Research Inc.
The company anticipates capital spending of between $70 million and $80 million.
الملفات المرفقه:
دورة المؤشرنت للتحليل الفني
50 دينار كويتي